Wednesday, July 8, 2026

Patent intelligence · US

US 8450358

Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

granted A61KA61K31/407A61PA61P1/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 7
Applicant portfolio 106
Patent details — US 8450358
Jurisdiction
US
Status
granted
Grant date
May 28, 2013
Expiration
May 23, 2033
Claims
3
CPC classes
A61K, A61K31/407, A61P, A61P1/00
View on Google Patents ↗

Quick answer

US 8450358 (Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
3
CPC classes
A61K, A61K31/407, A61P, A61P1/00, A61P1/02, A61P1/04

More from Xenon Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12319657

    Solid state crystalline forms of a selective potassium channel modulator

    Xenon Pharmaceuticals Inc. · Expires May 29, 2045

    granted
  2. US 12178811

    Methods of treating depressive disorders

    Xenon Pharmaceuticals Inc. · Expires Dec 26, 2044

    granted
  3. US 12171759

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. · Expires Dec 19, 2044

    granted
  4. US 11957675

    Methods and uses for treating anhedonia

    Xenon Pharmaceuticals Inc. · Expires Apr 11, 2044

    granted
  5. US 11325902

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires May 5, 2042

    granted
  6. US 11299490

    Benzenesulfonamide compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires Apr 7, 2042

    granted
  7. US 11203572

    Substituted benzamides and methods of use thereof

    Xenon Pharmaceuticals Inc. · Expires Dec 16, 2041

    granted
  8. US 11174268

    Benzenesulfonamide compouds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Expires Nov 11, 2041

    granted

Frequently asked questions

What is US patent 8450358?

US 8450358 (Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents) is held by Xenon Pharmaceuticals Inc.. Status: granted. Granted May 28, 2013. Expires May 23, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8450358?

Xenon Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 106 pharmaceutical patents for this assignee.

When does US 8450358 expire?

Our index shows an expiration date of May 23, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.